Get in Touch with our Immune Monitoring Experts
Advance novel CAR cell therapies with optimal CAR Dextramer® reagents:
- High-avidity multimer technology: The Dextramer® backbone ensures high-avidity, resulting in sensitive detection - even of lowly expressed CAR cells.
- Antigen-based detection: CAR Dextramer® reagents directly detect CAR expression and also verify CAR–antigen binding.
- Broad applicability: CAR Dextramer® is easily customizable - ideally for novel or non-ScFv-based constructs. No need to redesign when the CAR construct changes.
- Rapid staining protocol: Strong detection in half the time! With minimal wash steps, our protocol eases your workflow and minimizes handling of your cell samples.
- Simultaneous phenotyping: Detect your CAR cells alongside key surface markers such as CCR7 and CD45, for efficient phenotyping.
Accurate detection of CAR cells is pivotal to their development and translation. However, as CAR therapies become more diverse, reagent flexibility to detect novel CAR constructs and their precise characterization becomes paramount. This is where existing staining reagents are limited.
CAR Dextramer® reagents stand out as a high-avidity multimer technology offering a faster and more flexible alternative to anti-idiotype antibodies. Instead of relying on custom antibody development, our reagents use the natural antigen–CAR interaction to directly confirm binding and expression. CAR Dextramer® can be designed to detect virtually any CAR construct, including bivalent or gated CARs.
Custom CAR Dextramer® reagents can be produced in a matter of weeks at a fraction of the cost of custom anti-idiotype antibodies.
Off-the-shelf CAR Dextramer® reagents are available for CD19 – ask us about new targets coming soon including BCMA, MSLN and more!
See the results obtained by BioNTech SE when they tested CAR Dextramer® CD19:
Read the Blog: “A Comparison of CAR Detection Reagents”
"We recommend direct detection of the CAR to determine the % of CAR-positive cells."
- FDA. Draft Guidance for Industry:
Considerations for the development of CAR T Cell Products 03/2022
"I have already recommended Immudex reagents to current and former colleagues because I am satisfied with the quality of the products and the customer support."
- Scientist, Pharmaceutical Company